---
schema_version: "secwatch.filing_event.v1"
accession: "0000819050-23-000040"
form_type: "8-K"
ticker: null
cik: "0000819050"
company_name: "Fresh Tracks Therapeutics, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T10:23:57.790660+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Fresh Tracks Therapeutics receives Nasdaq bid-price non-compliance notice; board member resigns

## Summary
- Nasdaq notified Fresh Tracks on Apr 24, 2023 that bid price closed below $1.00 for 30 consecutive business days.
- Company has 180 calendar days (until Oct 23, 2023) to regain compliance; possible 180-day extension if eligible.
- Director Gary A. Lyons will resign at 2023 annual meeting due to overboarding concerns; no disagreement with company.
- Company monitoring bid price and considering options, but no assurance of regaining compliance or avoiding delisting.

## SEC filing metadata
- accession: 0000819050-23-000040
- form_type: 8-K
- cik: 0000819050
- company_name: Fresh Tracks Therapeutics, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/819050/000081905023000040/0000819050-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/819050/000081905023000040/frtx-20230421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000819050-23-000040
- JSON: https://secwatch.observer/filing/0000819050-23-000040.json
- Plain text: https://secwatch.observer/filing/0000819050-23-000040.txt

## Key facts
- Listing & Compliance Notices
  Fresh Tracks Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: April 24, 2023, Fresh Tracks Therapeutics, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 per share for 30 consecutive business days, the Company does not comply with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The notification has no immediate effect on the listing of the Company’s comm
  evidence_url: https://www.sec.gov/Archives/edgar/data/819050/000081905023000040/0000819050-23-000040-index.htm
- Executive change
  Gary A. Lyons departed as Director at Fresh Tracks Therapeutics, Inc..
  - Action: resign
  - Role: Director
  source text: On April 21, 2023, Gary A. Lyons informed the Company that he will resign from the Board of Directors on the date of the Company’s 2023 annual meeting of stockholders, because of overboarding concerns under proxy advisor and other institutional investor policies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/819050/000081905023000040/0000819050-23-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.